Work

What is the ideal treatment for advanced non-small-cell lung cancer with PD-L1 level ≥50%? Is mono immunotherapy enough?

Year: 2024

Type: article

Abstract: In recent years, the classification of advanced non-small-cell lung cancer (NSCLC) has been based on both molecular and pathological features. In non-oncogenic NSCLC (without EGFR, EML-ALK fusion, ...

Source: Future Oncology

DOI: 10.1080/14796694.2024.2414731

Authors: Burak Bilgin, Sebnem Yucel, Mehmet Ali Nahit Sendur, Bulent Yalcin

Institutions: Ankara Yıldırım Beyazıt University, Ankara Bilkent City Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W4404704037

FWCI:

Cites: 15

Cited by:

Related to: 10